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Photosensitizing Agents and the Risk
of Non-Melanoma Skin Cancer: A
Population-Based Case–Control Study
Zaineb H. Makhzoumi1 and Sarah T. Arron1
Robinson et al. report a population-based case–control study to examine the
association between a history of photosensitizing medication use and non-
melanoma skin cancer. They report an increased risk of basal cell carcinoma
with tetracycline use and of squamous cell carcinoma with diuretic use.
Appropriate counseling regarding sun exposure may reduce skin cancer in
patients exposed to these medications.
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It is well known that UVR has an
important role in the development of
non-melanoma skin cancer (NMSC).
Certain medications, designated as
either phototoxic or photoallergic, can
increase the skin’s susceptibility to
UVR, thereby potentially increasing the
risk of developing NMSC (Stern, 1998).
In this issue, Robinson et al. (2013)
examine the association between the
use of photosensitizing medications
and the subsequent development of
NMSC. The authors report a significant
increase in the risk of squamous cell
carcinoma (SCC), basal cell carcinoma
(BCC) and early-onset BCC in those who
reported a history of photosensitizing
medication use. The authors put forth
data gathered from their case–control
study, showing an odds ratio of nearly
2.0 for early-onset BCC in those with a
history of tetracycline use, and an odds
ratio of 1.3 for SCC in those with a
history of diuretic use.
A major strength of this study is in the
rigorous attention paid to the study
population, including strict inclusion
and exclusion criteria, and every
attempt made to match both the cases
and controls on all demographics.
Additionally, the authors used patient
interviews to capture and adjust for
important potential confounders such
as skin reactions to first summer sun
exposure, history of sunburn, and cumu-
lative lifetime sun exposure.
Another strength of this study was the
histological confirmation of all cases of
NMSC. This allowed the authors to
distinguish between SCC and BCC.
Of interest, the authors pinpoint that
photosensitizing medications appear to
increase the risk of SCC in patients with
a tendency to sunburn. Another finding
of interest was the association between
photosensitizing medications and the
risk of BCC before age 50.
The main limitation of this otherwise
excellent study lies in the retrospective
capture of self-reported medication use.
The inherent problem with this design is
the potential for recall bias, in which
cases and controls recall exposures dif-
ferently, with cases being more likely to
dig through their history and remember
a remote medication use in the hopes
that it may explain their disease. It is
doubtful that there will ever be a rando-
mized, controlled trial in this area,
and prospective studies of medication
exposure with skin cancer as an out-
come would require long-term follow-
up. Therefore, these data represent
the best we are likely to acquire in this
field.
A future study combining medica-
tion data capture from pharmacy or
medical records with the patient inter-
view data presented here might validate
this data.
Results in context
Several groups have reported an asso-
ciation between photosensitizing medi-
cation use and NMSC; this study builds
on prior research and extends the find-
ings to an American population. The
authors report that cardiovascular med-
ications, particularly diuretics, were
associated with 1.3-fold increased odds
of SCC, though not of BCC. This sup-
ports the previous findings of a Eur-
opean study reporting 1.6-fold
increased odds of SCC in those with a
history of thiazide diuretic use (de Vries
et al., 2012). In contrast, a large Danish
cohort study found no association
between thiazade diuretics and SCC,
but did reveal an increased risk of SCC
in patients with a history of furosemide
use (Kaae et al., 2010). It is possible that
the indications for use are a confounder
linking cardiovascular disease with SCC
risk; future studies will be needed to
clarify these findings.
A publication based on the compre-
hensive Rotterdam Study reported an
association between high-level use of
diuretics and BCC; that study did not
evaluate SCC risk (Ruiter et al., 2010).
Neither Robinson et al. (2013) nor Kaae
et al. found an association between
diuretic use and BCC; de Vries et al.
did observe an association between
thiazides and BCC, but this finding lost
significance after correction for multiple
hypothesis testing. The heterogeneity
observed in these studies may result
from the study populations or from
methods of data collection and model
construction.
Robinson et al. (2013) also report an
association between tetracycline use
and BCC, with an odds ratio of 1.8
for any BCC diagnosis and 2.0 for
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early-onset BCC. This is similar to the
1.3-fold increased odds of BCC with
tetracycline use reported by Kaae et al.
Interestingly, that study also reported a
2-fold increased risk of BCC with
isotretinoin use, supporting Robinson’s
hypothesis that acne as an indication
may increase BCC risk as well. Further
studies focused on acne patients may
resolve whether the increased BCC risk
observed is due to the medication or the
underlying pathology.
Conclusion
Robinson et al. (2013) report their
findings about the association between
photosensitizing medication use and
the risk of NMSC, in particular the
association of tetracyclines with BCC
risk and diuretics with SCC risk. This
clinical relevance of these associations
is still uncertain but it seems reasonable
that patients prescribed these medi-
cations should be counseled regarding
sun protection. This information needs
to be disseminated to our colleagues in
primary care and internal medicine, as
they are the primary prescribers of these
medications. Dermatologists should also
counsel our acne patients regarding sun
protection with long-term tetracycline
use. Taking a history of photosensitiz-
ing medication use should also become
part of screening for skin cancer risk,
along with a lifetime history of sun
exposure, Fitzpatrick skin type, and
exposure to tanning beds. Future
studies in this area, dedicated to speci-
fic medications and exposure patterns,
will validate the reported associations
and suggest additional steps toward the
detection and ultimate prevention of
skin cancer.
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Clinical Implications
 Robinson et al. report a population-based case–control study that found
an increased risk of basal cell carcinoma with tetracycline use and of
squamous cell carcinoma with diuretic use.
 It seems reasonable that patients prescribed these medications should be
counseled regarding sunlight protection.
 Taking a history of photosensitizing medication use should be part of
screening for skin cancer risk.
Phacomatosis Pigmentokeratotica Is a
‘‘Pseudodidymosis’’
Rudolf Happle1
In phacomatosis pigmentokeratotica, papular nevus spilus coexists with nevus
sebaceus. The disorder was thought to be a didymosis with early postzygotic
recombination. In this issue, however, Groesser and co-workers provide a new
concept. Both nevi originate from a single heterozygous HRAS mutation in a
pluripotent progenitor cell. This new understanding has implications for other
proposed examples of didymosis in humans.
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Phacomatosis pigmentokeratotica (PPK)
is characterized by the coexistence of
nevus sebaceus and papular nevus spilus
(Figure 1). The disorder has so far been
considered to represent an example of
twin spotting or didymosis, which is why
it has also been called ‘‘didymosis spilo-
sebacea’’ (Happle, 2010). These binary
nevi are often associated with various
extracutaneous defects. Seventeen years
ago, we proposed the hypothesis that the
disorder represents a nonallelic twin-
spot phenomenon (Happle et al., 1996).
Accordingly, the two nevi would have
originated from an early event of
postzygotic recombination, resulting in
a loss of heterozygosity and, thus, be
homozygous at either of the two loci
that were situated in different regions on
a pair of homologous chromosomes
(Happle, 1999). Thus far, this etiological
concept had been accepted widely
(Boente et al., 2000; Martı´nez-Menchon
et al., 2005; Bouthors et al., 2006;
Gruson et al., 2006; Oh et al, 2012),
although molecular proof was lacking.
In the present issue, however,
Groesser et al. (2013) present
molecular findings that disprove the
twin-spot hypothesis. From an analysis
of six patients affected with PPK, they
provide convincing evidence that both
the sebaceous nevus and the papular
nevus spilus originate from the same
postzygotic HRAS mutation, being
present in a heterozygous state. Hence,
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